51 Active Studies

Depression Clinical Trials

Find actively recruiting research studies for depression. Connect with study sites near you and explore new treatment options.

51
Active Trials
147+
Locations
17,102
Participants Needed

Recruiting Studies

RecruitingNCT06433635

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic tri...

10 locations(Birmingham, Bloomington, Baltimore)
2,726 participants
Massachusetts General Hospital
View Study Details
RecruitingNCT06029439

Study to Assess the Safety and Effectiveness of NMRA-335140-501

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who ...

10 locations(Huntsville, Phoenix, Bentonville)
1,000 participants
Neumora Therapeutics, Inc.
View Study Details
RecruitingNCT06559306

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant i...

10 locations(Birmingham, Chandler, Tucson)
752 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD....

10 locations(Little Rock, Orange, Pico Rivera)
600 participants
Neurocrine Biosciences
View Study Details
RecruitingNCT05711940

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)...

10 locations(Gilbert, Bellflower, Encino)
568 participants
COMPASS Pathways
View Study Details
RecruitingNCT07196501

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in pa...

4 locations(Melbourne, Miami Gardens, O'Fallon)
550 participants
Neurocrine Biosciences
View Study Details
RecruitingNCT06830044

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder...

2 locations(Little Rock, Richardson)
500 participants
Vanda Pharmaceuticals
View Study Details
RecruitingNCT05850689

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical...

10 locations(Huntsville, Pico Rivera, Farmington)
470 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingNCT06605105

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD....

2 locations(Hollywood, Atlanta)
468 participants
Cybin IRL Limited
View Study Details
RecruitingNCT06775379

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...

10 locations(Phoenix, Little Rock, Rogers)
450 participants
Xenon Pharmaceuticals Inc.
View Study Details
RecruitingNCT07076407

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...

9 locations(Sherman Oaks, Atlanta, Orland Park)
450 participants
Xenon Pharmaceuticals Inc.
View Study Details
RecruitingNCT03996265

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depr...

10 locations(Anchorage, Anchorage, Anchorage)
422 participants
University of Rochester NCORP Research Base
View Study Details
RecruitingNCT06713616

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for us...

6 locations(Milford, New Haven, Atlanta)
400 participants
Yale University
View Study Details
RecruitingNCT07172516

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder wh...

5 locations(Little Rock, Rogers, Jacksonville)
400 participants
Xenon Pharmaceuticals Inc.
View Study Details
RecruitingNCT06372964

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I o...

10 locations(Dothan, Little Rock, Anaheim)
384 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingNCT04777357

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of ...

10 locations(Bentonville, Anaheim, Beverly Hills)
380 participants
AbbVie
View Study Details
RecruitingNCT04560673

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

This phase II trial investigates how well duloxetine and neurofeedback training work in treating patients with chemotherapy induced peripheral neuropathy. Duloxetine is a type of serotonin and norepin...

2 locations(Houston, Houston)
380 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingNCT07065240

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive diso...

10 locations(Chino, Garden Grove, Glendale)
360 participants
Seaport Therapeutics
View Study Details
RecruitingNCT06223880

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with m...

10 locations(Bellflower, Lafayette, Oceanside)
350 participants
Axsome Therapeutics, Inc.
View Study Details
RecruitingNCT04041479

Biomarker-guided rTMS for Treatment Resistant Depression

Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research ...

2 locations(Stanford, New York)
348 participants
Weill Medical College of Cornell University
View Study Details
RecruitingNCT06058039

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Dis...

10 locations(Cerritos, Irvine, Long Beach)
332 participants
Neumora Therapeutics, Inc.
View Study Details
RecruitingNCT06058013

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive ...

10 locations(Encino, Garden Grove, Los Alamitos)
332 participants
Neumora Therapeutics, Inc.
View Study Details
RecruitingNCT05922878

Study of ALTO-300 in MDD

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics....

10 locations(Phoenix, Phoenix, Yuma)
321 participants
Alto Neuroscience
View Study Details
RecruitingNCT05398484

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

2 locations(Aurora, New York)
300 participants
NYU Langone Health
View Study Details
RecruitingNCT06704594

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle...

2 locations(Baltimore, Charlottesville)
288 participants
Johns Hopkins University
View Study Details
RecruitingNCT06308653

Psilocybin for Major Depressive Disorder (MDD)

Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. P...

10 locations(Birmingham, Fayetteville, Little Rock)
240 participants
Usona Institute
View Study Details
RecruitingNCT06633016

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who ha...

10 locations(Birmingham, Chandler, Phoenix)
230 participants
Autobahn Therapeutics, Inc.
View Study Details
RecruitingNCT06564818

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD....

10 locations(Phoenix, Tucson, Tucson)
220 participants
Cybin IRL Limited
View Study Details
RecruitingNCT06125951

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the...

10 locations(Carlsbad, Orange, Sherman Oaks)
220 participants
Actinogen Medical
View Study Details
RecruitingNCT04422652

Combination of Novel Therapies for CKD Comorbid Depression

The overall goal of the study is to determine if treatment of a Major Depressive Disorder (MDD) improves the outcomes of patients with chronic kidney disease (CKD). We showed that MDD is present in 25...

4 locations(Stony Brook, Dallas, Dallas)
201 participants
Stony Brook University
View Study Details
RecruitingNCT06656416

ALTO-100 in Bipolar Disorder With Depression (BD-D)

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depr...

10 locations(Chandler, Phoenix, Yuma)
200 participants
Alto Neuroscience
View Study Details
RecruitingNCT06786624

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression....

6 locations(Orange, Maitland, Boston)
200 participants
Neurocrine Biosciences
View Study Details
RecruitingNCT06963021

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression....

9 locations(Los Angeles, Cromwell, Farmington)
200 participants
Neurocrine Biosciences
View Study Details
RecruitingNCT06836063

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD)....

10 locations(Anaheim, Glendale, Oceanside)
195 participants
Suven Life Sciences Limited
View Study Details
RecruitingNCT05587517

A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Hypotheses 1a and 1b: Compared to Supportive Conversation arm, the EMPOWER intervention will significantly decrease surrogate decision makers' symptoms of grief and Post Traumatic Stress Disorder (PTS...

3 locations(Miami, New York, New York)
172 participants
Weill Medical College of Cornell University
View Study Details
RecruitingNCT06547489

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 r...

10 locations(Birmingham, Huntsville, Encino)
164 participants
Syndeio Biosciences, Inc
View Study Details
RecruitingNCT06605599

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participant...

10 locations(Dothan, Anaheim, Colton)
160 participants
AbbVie
View Study Details
RecruitingNCT03913845

The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling

Stress urinary incontinence affects millions of women worldwide and has a profound impact on the quality of life of older individuals, their subjective health status, levels of depression and need for...

4 locations(Bethel Park, Jefferson Hills, Pittsburgh)
150 participants
West Penn Allegheny Health System
View Study Details
RecruitingNCT06524830

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatm...

10 locations(Fayetteville, Rogers, Garden Grove)
142 participants
atai Therapeutics, Inc.
View Study Details
RecruitingNCT06941844

A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge...

10 locations(Fayetteville, Little Rock, La Jolla)
140 participants
Mind Medicine, Inc.
View Study Details
RecruitingNCT06785012

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participant...

10 locations(Huntsville, Chandler, Phoenix)
124 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT06269146

Pramipexole to Enhance Social Connections

This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 pa...

2 locations(San Diego, New York)
108 participants
University of California, San Diego
View Study Details
RecruitingNCT04469959

Dopaminergic Dysfunction in Late-Life Depression

Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction,...

2 locations(Pittsburgh, Nashville)
100 participants
Vanderbilt University Medical Center
View Study Details
RecruitingNCT05774665

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not respond...

3 locations(Atlanta, Boston, Salt Lake City)
80 participants
Massachusetts General Hospital
View Study Details
RecruitingNCT06979544

A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symp...

10 locations(Anahiem, Canoga Park, Miami)
80 participants
Lipocine Inc.
View Study Details
RecruitingNCT06391593

PD, PK, and Safety of ALTO-203 in Patients With MDD

The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, ...

10 locations(Tucson, Oceanside, Torrance)
60 participants
Alto Neuroscience
View Study Details
RecruitingNCT05849038

Inflammation and Depression in People With HIV

The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia a...

2 locations(Atlanta, Atlanta)
60 participants
Emory University
View Study Details
RecruitingNCT05004987

Aβ Dynamics in LLMD

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depressio...

2 locations(New York, Orangeburg)
60 participants
NYU Langone Health
View Study Details
RecruitingNCT06869187

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment(s) shows effects on brain chemistry that may correlate with antidepressive effects. This is a single t...

6 locations(Cromwell, Cherry Hill, Marlton)
35 participants
Autobahn Therapeutics, Inc.
View Study Details
RecruitingNCT06620042

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI....

2 locations(Cleveland, Ohio City)
20 participants
Brian Barnett
View Study Details
RecruitingNCT04400266

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

Traumatic brain injuries (TBIs) are common. Post-TBI depression is associated with anxiety, aggression, fatigue, distractibility, anger, irritability, and rumination. The current research group conduc...

2 locations(Boston, Charlestown)
10 participants
Massachusetts General Hospital
View Study Details

Frequently Asked Questions

What clinical trials are available for Depression?

There are currently 51 actively recruiting clinical trials for depression. These studies are testing new treatments, therapies, and interventions at research sites across 147 cities.

How do I join a Depression clinical trial?

To join a depression clinical trial: 1) Browse the available studies above, 2) Click on a study that interests you, 3) Complete the eligibility form, and 4) A study coordinator will contact you.

Are clinical trials free for patients?

Yes, clinical trial participation is free. In most studies, the treatment, medical tests, and doctor visits related to the trial are provided at no cost. Some studies may also compensate for time and travel.

Can I leave a clinical trial if I change my mind?

Yes, participation in any clinical trial is completely voluntary. You can withdraw at any time, for any reason, without affecting your regular medical care.